source
- Dyne Therapeutics receives early 2027 FDA decision date for Duchenne therapy, analysts anticipate smooth reviewDyne Therapeutics' investigational Duchenne muscular dystrophy therapy, zeleciment rostudirsen, has had its BLA accepted by the FDA with a target action date of Jan 21, 2027. Analysts at Oppenheim…
- Samsung Biologics proposes $1.8B acquisition of PolyPeptide to enter fast-growing obesity peptide marketSamsung Biologics, a South Korean contract development and manufacturing organization, announced an offer to acquire Swiss CDMO PolyPeptide for CHF 1.46 billion (about $1.8 billion). PolyPeptide s…BioSpace · 1mo agoDealPositive